Enyu Imai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Enyu Imai has a total of 643 co-authors. Here are the top co-authors by number of shared publications:
Masaru Horio
Osaka University Graduate School of Medicine
7 shared publicationsAkira Hishida
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
6 shared publicationsHirofumi Makino
Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
6 shared publicationsSeiichi Matsuo
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
6 shared publications- Yoshitaka Isaka
Department of Nephrology, The University of Osaka Graduate School of Medicine, Osaka, Japan
6 shared publications Kunihiro Yamagata
Department of Nephrology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
5 shared publications
Latest Publications
- 1 January 2012
- Vol. 54 (4)
[Guidelines for iodinated contrast in a patient with CKD 2012].
- 1 January 2010
- Vol. 52 (1) , 13-27
[Clinical study on nephrology].
- 1 September 2009
- Published by Elsevier in Kidney International
- Vol. 76 (5) , 477-480
A novel classification for IgA nephropathy
- 1 September 2009
- Published by Elsevier in Kidney International
- Vol. 76 (5) , 477-480
A novel classification for IgA nephropathy
- 1 February 2009
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 13 (1) , 61-65
Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics
Olmesartan medoxomil is a new angiotensin-2 receptor blocker (ARB). Its pharmacokinetics in hemodialysis patients has not been investigated. We evaluated the pharmacokinetics of olmesartan medoxomil in six patients on maintained hemodialysis. We divided these six patients into two groups; one group (n = 3) took the drug when hemodialysis started (HD day group), and the other group (n = 3) took in the morning on non-dialysis day (non HD day group). In each group, plasma concentrations of olmesartan were evaluated seven points after drug administration. In each point, blood pressure and heart rate were also measured. On HD day group, plasma concentrations in upstream of dialyser were compared with those in downstream of dialyser in three points. The area under the plasma concentration–time curve (AUC) in HD day group had no remarkable difference from those in non-HD day group. Another pharmacokinetic parameter, such as maximum plasma drug concentration (Cmax), biological half-life (t1/2) and time to reach Cmax (tmax), were almost similar in both groups. Blood pressure and heart rate showed the same consequence as well. This result suggests that plasma concentration of olmesartan medoxomil does not decrease during hemodialysis, and that it is not necessary to change prescription on hemodialysis day or not.
- 1 February 2009
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 13 (1) , 61-65
Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics
Olmesartan medoxomil is a new angiotensin-2 receptor blocker (ARB). Its pharmacokinetics in hemodialysis patients has not been investigated. We evaluated the pharmacokinetics of olmesartan medoxomil in six patients on maintained hemodialysis. We divided these six patients into two groups; one group (n = 3) took the drug when hemodialysis started (HD day group), and the other group (n = 3) took in the morning on non-dialysis day (non HD day group). In each group, plasma concentrations of olmesartan were evaluated seven points after drug administration. In each point, blood pressure and heart rate were also measured. On HD day group, plasma concentrations in upstream of dialyser were compared with those in downstream of dialyser in three points. The area under the plasma concentration–time curve (AUC) in HD day group had no remarkable difference from those in non-HD day group. Another pharmacokinetic parameter, such as maximum plasma drug concentration (Cmax), biological half-life (t1/2) and time to reach Cmax (tmax), were almost similar in both groups. Blood pressure and heart rate showed the same consequence as well. This result suggests that plasma concentration of olmesartan medoxomil does not decrease during hemodialysis, and that it is not necessary to change prescription on hemodialysis day or not.
- Open Access
- 1 January 2009
- Published by Oxford University Press (OUP) in NDT Plus
- Vol. 2 (Supplement) , ii704
Renal transplantation - clinical studies - 3
Persistent hyperparathyroidism (HPT) is one of the complications observed in more than 25% of post-transplant recipients 1 year after successful kidney transpla
- 1 January 2009
- Published by Oxford University Press (OUP) in NDT Plus
- Vol. 2 (Supplement) , ii704
Open AccessRenal transplantation - clinical studies - 3
Persistent hyperparathyroidism (HPT) is one of the complications observed in more than 25% of post-transplant recipients 1 year after successful kidney transpla
- Open Access
- 1 January 2009
- Published by Oxford University Press (OUP) in NDT Plus
- Vol. 2 (Supplement) , ii1733
Epidemiology and CKD - 2
To identify people with chronic kidney disease, at least serum creatinine is needed, but it has been shown that screening for CKD in general population is not c
- 1 January 2009
- Published by Oxford University Press (OUP) in NDT Plus
- Vol. 2 (Supplement) , ii1733
Open AccessEpidemiology and CKD - 2
To identify people with chronic kidney disease, at least serum creatinine is needed, but it has been shown that screening for CKD in general population is not c
- Open Access
- 1 January 2008
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 31 (3) , 433-441
Slower Decline of Glomerular Filtration Rate in the Japanese General Population: A Longitudinal 10-Year Follow-Up Study
The prevalence of stage 3 to 5 chronic kidney disease (CKD) in Japan (18.7%) is considerably higher than that in the United States (4.5%). This study investigated in the Japanese general population whether this higher prevalence of CKD might reflect to a progressive decline of renal function, and in turn to the increased risk of end-stage renal disease. A decline in renal function over 10 years was examined in 120,727 individuals aged 40 years or older who participated in the annual health examination program of the two periods over 10 years, 1988–1993 and 1998–2003. Renal function was assessed with estimated glomerular filtration rate (GFR) using the abbreviated Modification of Diet in Renal Disease (MDRD) Study equation modified by a Japanese coefficient. The rate of GFR decline in the participants was 0.36 mL/min/1.73 m2/year on average. In the male population aged 50–79, the mean rate of GFR decline was significantly higher in the presence of hypertension than in its absence. The rate of GFR decline was more than two times higher in participants with proteinuria than in those without proteinuria in both sexes. The rate was significantly higher in participants with an initial GFR 2 among the groups younger than age 70 and in participants with an initial GFR 2 in the group with age 70–79. Based on the slow rate of GFR decline, we concluded that the decline in renal function progresses slowly in the Japanese general population. Hypertension, proteinuria and lower GFR were found to be significant risk factors for a faster decline of GFR.
- 1 January 2008
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 31 (3) , 433-441
Open AccessSlower Decline of Glomerular Filtration Rate in the Japanese General Population: A Longitudinal 10-Year Follow-Up Study
The prevalence of stage 3 to 5 chronic kidney disease (CKD) in Japan (18.7%) is considerably higher than that in the United States (4.5%). This study investigated in the Japanese general population whether this higher prevalence of CKD might reflect to a progressive decline of renal function, and in turn to the increased risk of end-stage renal disease. A decline in renal function over 10 years was examined in 120,727 individuals aged 40 years or older who participated in the annual health examination program of the two periods over 10 years, 1988–1993 and 1998–2003. Renal function was assessed with estimated glomerular filtration rate (GFR) using the abbreviated Modification of Diet in Renal Disease (MDRD) Study equation modified by a Japanese coefficient. The rate of GFR decline in the participants was 0.36 mL/min/1.73 m2/year on average. In the male population aged 50–79, the mean rate of GFR decline was significantly higher in the presence of hypertension than in its absence. The rate of GFR decline was more than two times higher in participants with proteinuria than in those without proteinuria in both sexes. The rate was significantly higher in participants with an initial GFR 2 among the groups younger than age 70 and in participants with an initial GFR 2 in the group with age 70–79. Based on the slow rate of GFR decline, we concluded that the decline in renal function progresses slowly in the Japanese general population. Hypertension, proteinuria and lower GFR were found to be significant risk factors for a faster decline of GFR.
- Open Access
- 1 January 2008
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 31 (1) , 59-67
Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker
Although dual blockade of the renin-angiotensin-aldosterone system (RAAS) with the combination of an angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) is generally well-established as a treatment for nephropathy, this treatment is not fully effective in some patients. Based on the recent evidence implicating aldosterone in renal disease progression, this study was conducted to examine the efficacy of blockade with three different mechanisms by adding an aldosterone blocker in patients who do not respond adequately to the dual blockade. A 1-year randomized, open-label, multicenter, prospective controlled study was conducted, in which 32 non-diabetic nephropathy patients with proteinuria exceeding 0.5 g/day were enrolled after more than 12 weeks of ACE-I (5 mg enalapril) and ARB (50 mg losartan) combination treatment. These patients were allocated into two groups of 16 patients each: a triple blockade group in which 25 mg of spironolactone daily was added to the ACE-I and ARB combination treatment, and a control group in which 1 mg of trichlormethiazide or 20 mg of furosemide was added to the combination treatment instead of spironolactone depending upon the creatinine level. After 1 year of treatment, the urinary protein level decreased by 58% (ppHypertens Res 2008; 31: 59−67)
- 1 January 2008
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 31 (1) , 59-67
Open AccessEffect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker
Although dual blockade of the renin-angiotensin-aldosterone system (RAAS) with the combination of an angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) is generally well-established as a treatment for nephropathy, this treatment is not fully effective in some patients. Based on the recent evidence implicating aldosterone in renal disease progression, this study was conducted to examine the efficacy of blockade with three different mechanisms by adding an aldosterone blocker in patients who do not respond adequately to the dual blockade. A 1-year randomized, open-label, multicenter, prospective controlled study was conducted, in which 32 non-diabetic nephropathy patients with proteinuria exceeding 0.5 g/day were enrolled after more than 12 weeks of ACE-I (5 mg enalapril) and ARB (50 mg losartan) combination treatment. These patients were allocated into two groups of 16 patients each: a triple blockade group in which 25 mg of spironolactone daily was added to the ACE-I and ARB combination treatment, and a control group in which 1 mg of trichlormethiazide or 20 mg of furosemide was added to the combination treatment instead of spironolactone depending upon the creatinine level. After 1 year of treatment, the urinary protein level decreased by 58% (ppHypertens Res 2008; 31: 59−67)
- 1 January 2008
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 31 (6) , 1101-1107
Chronic Kidney Disease Japan Cohort (CKD-JAC) Study: Design and Methods
Hypertension Research, official publication of the Japanese Society of Hypertension, publishes papers reporting original clinical and experimental research in the field of hypertension and related cardiovascular diseases.
- 1 January 2008
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 31 (6) , 1101-1107
Chronic Kidney Disease Japan Cohort (CKD-JAC) Study: Design and Methods
Hypertension Research, official publication of the Japanese Society of Hypertension, publishes papers reporting original clinical and experimental research in the field of hypertension and related cardiovascular diseases.
- 1 December 2007
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 50 (6) , 927-937
Modification of the Modification of Diet in Renal Disease (MDRD) Study Equation for Japan
- 1 December 2007
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 50 (6) , 927-937
Modification of the Modification of Diet in Renal Disease (MDRD) Study Equation for Japan